New England Journal of Medicine · 1 Oct 2026 · Editorial

Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease.

Dörner

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

Chronic Pancreatitis: Mechanisms of Inflammation, Pathways of Progression and Emerging Therapeutic Strategies.
Gastroenterology · 1 Oct 2026 · Review
Chronic pancreatitis involves progressive inflammation and fibrosis, with early-stage mechanisms and biomarkers remaining poorly understood, hindering disease-modifying treatments.
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42055197
Open in JClub
Obexelimab for the Treatment of IgG4-Related Disease.
New England Journal of Medicine · 1 Oct 2026 · Randomized Controlled Trial
Obexelimab significantly delays disease flares and reduces glucocorticoid use in IgG4-related disease, with a hazard ratio of 0.44 and fewer flares compared to placebo.
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42233621
Open in JClub
Histopathology matters for imaging and clinical correlations in primary sclerosing cholangitis.
Journal of hepatology · 1 Sept 2026 · Letter
Read the brief in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42202960
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read